Squamous cell carcinoma of the lung chemotherapy: Difference between revisions
| Line 25: | Line 25: | ||
:*Docetaxel | :*Docetaxel | ||
:*Pemetrexed | :*Pemetrexed | ||
*Chemotherapy is indicated as adjuvant for stage IB, II, and III squamous cell carcinoma of the lung | *Chemotherapy is indicated as adjuvant for stage IB, II, and III squamous cell carcinoma of the lung. The predominant treatment of choice for squamous cell carcinoma of the lung is surgical resection | ||
*Platinum-based chemotherapy (cisplatin, carboplatin, etoposide, irinotecan) are the mainstay of squamous cell carcinoma of the lung | *Platinum-based chemotherapy (cisplatin, carboplatin, etoposide, irinotecan) are the mainstay of squamous cell carcinoma of the lung | ||
*Platinum-based chemotherapy consists of four to six cycles | *Platinum-based chemotherapy consists of four to six cycles | ||
Revision as of 16:52, 7 March 2016
|
Squamous Cell Carcinoma of the Lung Microchapters |
|
Differentiating Squamous Cell Carcinoma of the Lung from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Squamous cell carcinoma of the lung chemotherapy On the Web |
|
American Roentgen Ray Society Images of Squamous cell carcinoma of the lung chemotherapy |
|
Squamous cell carcinoma of the lung chemotherapy in the news |
|
Directions to Hospitals Treating Squamous cell carcinoma of the lung |
|
Risk calculators and risk factors for Squamous cell carcinoma of the lung chemotherapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shanshan Cen, M.D. [2] Maria Fernanda Villarreal, M.D. [3]
Overview
Chemotherapy is indicated for squamous cell carcinoma of the lung stage (IB, II, and III) as adjuvant therapy. The predominant treatment of choice for squamous cell carcinoma of the lung is surgical resection. Chemotherapy and chemoradiation may be required upon histological subtype of squamous cell carcinoma of the lung, location, size, and lymph node involvement. Commonly used chemotherapeutic agents, include: erlotinib, paclitaxel, docetaxel, carboplatin, etoposide or vinorelbine.[1]
Chemotherapy
- Initial chemotherapy for patients with squamous cell carcinoma of the lung will depend on molecular testing (presence of genetic mutations)
- Platinum-based chemotherapy is the treatment of choice for the management of patients with squamous cell carcinoma of the lung
- Erlotinib is the first-line treatment for patients with squamous cell carcinoma of the lung whose cancer has spread to other parts of the body and that has certain types of epidermal growth factor receptor (EGFR) mutations.
- Chemotherapy regimen treatments, include:[1]
- Paclitaxel
- Cisplatin
- Erlotinib
- Afatinib
- Gefitinib
- Bevacizumab
- Crizotinib
- Vinorelbine
- Gemcitabine
- Carboplatin
- Etoposide
- Docetaxel
- Pemetrexed
- Chemotherapy is indicated as adjuvant for stage IB, II, and III squamous cell carcinoma of the lung. The predominant treatment of choice for squamous cell carcinoma of the lung is surgical resection
- Platinum-based chemotherapy (cisplatin, carboplatin, etoposide, irinotecan) are the mainstay of squamous cell carcinoma of the lung
- Platinum-based chemotherapy consists of four to six cycles
- To see more detailed information about the chemotherapeutic regimens in non-small cell lung cancer click here
Complications
- Medical therapy complications for squamous cell carcinoma of the lung will depend on the chemotherapeutic agent.
- Common chemotherapy complications, include:[1]
- Platinum-based chemotherapy, the main dose-limiting side effect of cancer treatment with platinum compounds, include:
- Other chemotherapeutic agent complications, include:
- Side effects symptoms of chemotherapeutic agents, include:
- Hair loss
- Loss of appetite
- Nausea
- Vomiting
- Diarrhea or constipation
- Easy bruising
- Fatigue